• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Verve Therapeutics Inc (NQ: VERV )

    6.310 -0.050 (-0.79%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Verve Therapeutics Inc

    < Previous 1 2
    ...
    4 5 6 7 8 9 10 11 Next >
    Verve Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
    From Verve Therapeutics
    Via GlobeNewswire
    Verve Therapeutics's Return On Capital Employed Insights
    Via Benzinga
    Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates
    From Verve Therapeutics
    Via GlobeNewswire
    Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
    From Verve Therapeutics
    Via GlobeNewswire
    Why Verve Therapeutics' Stock Dropped 26.33% on Monday
    A trial for the company's lead therapy was put on hold. 
    Via The Motley Fool
    Better Buy: Beam Therapeutics or Intellia Therapeutics?
    The two clinical-stage gene-editing companies have good long-term prospects. 
    Via The Motley Fool
    3 Deeply Undervalued Stocks That Could Double Your Money
    These cutting-edge biotech stocks hold tremendous upside potential. 
    Via The Motley Fool
    Verve Therapeutics Announces VERVE-101 Awarded Innovation Passport by the UK MHRA for the Treatment of Heterozygous Familial Hypercholesterolemia
    From Verve Therapeutics
    Via GlobeNewswire
    Being Cautious On Regulatory/Commercial Path, This Analyst Initiates Coverage On Verve Therapeutics
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023
    Via Benzinga
    7 CRISPR Stocks With the Best Long-Term Potential
    CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve. 
    Via InvestorPlace
    Cathie Wood Gets Elon Musk's Attention Over Gene-Editing Therapy Potential: 'Investors Chased The Dream Then. Now, They're Running Away'
    Cathie Wood of ARK Investment Management believes U.S. equity markets are the polar opposite of what they were in the 90s when investors chased their dreams. 
    Via Benzinga
    Verve Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
    From Verve Therapeutics
    Via GlobeNewswire
    10 Health Care Stocks Whale Activity In Today's Session
    This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
    Via Benzinga
    Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023?
    Crispr and Vertex are working toward the first submissions for a CRISPR-based product. 
    Via Investor's Business Daily
    Analyst Beefs Up Beam Therapeutics Price Target, Says 'Reward Is Now Skewed To Upside'
    Via Benzinga
    Why Third Harmonic Bio Shares Are Trading Lower By Over 78%? Here Are 40 Stocks Moving In Thursday's Mid-Day Session
    Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) jumped 69.6% to $0.2604 after gaining 17% on Wednesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. 
    Via Benzinga
    Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
    The growth-focused money manager is making moves. 
    Via The Motley Fool
    Cathie Wood Adds $7M Of This Clinical-Stage Biotech, Trims Stake In CVS-Target Signify Health
    Cathie Wood-led ARK Investment Management bought over 330,000 shares of clinical-stage biotechnology company Verve Therapeutics Inc (NASDAQ: VERV) at an estimated valuation of over $6.9 million, based... 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022
    Via Benzinga
    Why Iovance Biotherapeutics Shares Are Trading Higher By Around 19%? Here Are 40 Stocks Moving In Monday's Mid-Day Session
    Gainers Winc, Inc. (NYSE: WBEV) rose 88.5% to $0.3901 after dropping over 23% on Friday. Winc, last month, posted a Q3 loss of $0.33 per share. 
    Via Benzinga
    Gold Down 1%; China Pharma Shares Spike Higher
    U.S. stocks traded lower midway through trading, with the Dow Jones dropping over 200 points on Monday. 
    Via Benzinga
    VF Corp, Verve Therapeutics And Some Other Big Stocks Moving Lower On Monday
    U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Monday. Here are some big stocks recording losses in today’s session. 
    Via Benzinga
    US Stocks Start Week On Lower Note; Dow Tumbles 250 Points
    U.S. stocks traded lower this morning, with the Dow Jones falling around 250 points on Monday. 
    Via Benzinga
    Verve Therapeutics Stock Skids On The FDA's Long List Of Gene-Editing Concerns
    The company has a long list of issues to address to satisfy the FDA's worries. 
    Via Investor's Business Daily
    Looking Into Verve Therapeutics's Recent Short Interest
    Verve Therapeutics's (NASDAQ:VERV) short percent of float has fallen 10.98% since its last report. The company recently reported that it has 10.05 million shares sold short, which is 29.91% of all... 
    Via Benzinga
    Verve Therapeutics to Participate in Upcoming Investor Conferences
    From Verve Therapeutics
    Via GlobeNewswire
    Dow Surges 400 Points; Crude Oil Down 1%
    U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 400 points on Monday. 
    Via Benzinga
    Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
    Gainers 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Gainers 
    Via Benzinga
    < Previous 1 2
    ...
    4 5 6 7 8 9 10 11 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.